ストックスクリーナーアプリを入手
81.36
0.93%
-0.76
アフターアワーズ：
81.25
-0.11
-0.14%
Rhythm Pharmaceuticals Inc (RYTM) 最新ニュース
Vanguard Capital Management (RYTM) files Schedule 13G for 5.02% stake - Stock Titan
[ARS] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Board elections and Say-on-Pay on deck for Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan
Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN
Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential - MSN
Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Rhythm Pharma wins EU backing to expand Imcivree label - MSN
Rhythm Pharmaceuticals (RYTM): Precision Obesity Pivot Grabs Headlines - Insider Monkey
Rhythm Pharmaceuticals, Inc. (RYTM): Investor Outlook Reveals 60% Potential Upside In Biotech Sector - DirectorsTalk Interviews
RHYTHM PHARMACEUTICALS INC (RYTM) Fundamental Analysis & Valuation - ChartMill
Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Is RYTM a Good Stock to Buy? Bearish Thesis on Rhythm Pharmaceuticals - HarianBasis.co
M&T Bank Corp Invests $9.20 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now? - Insider Monkey
RYTM Technical Analysis | Trend, Signals & Chart Patterns | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill
RYTM (Rhythm Pharmaceuticals) tops Q4 2025 EPS estimates, posts 45.8 percent year-over-year revenue growth, shares dip 1.09 percent.Popular Market Picks - Xã Thanh Hà
Rhythm Pharmaceuticals (RYTM) Stock: Mistakes to Avoid (Technical Strength) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Rhythm Pharmaceuticals (NASDAQ:RYTM) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - 富途牛牛
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating - 富途牛牛
Goldman Sachs Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $158 - Moomoo
Assessing Rhythm Pharmaceuticals (RYTM) Valuation After A Recent Share Price Pullback - Sahm
Is Rhythm Pharmaceuticals (RYTM) Still Attractive After A 48.9% One‑Year Share Price Gain - Sahm
Avoiding Lag: Real-Time Signals in (RYTM) Movement - Stock Traders Daily
Rhythm Pharmaceuticals (RYTM) reports phase 3 EMANATE trial topline results for setmelanotide - MSN
Wall Street Zen Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to Hold - MarketBeat
Risk Analysis: Is Rhythm Pharmaceuticals Inc gaining market share2026 Outlook & Reliable Price Action Trade Plans - baoquankhu1.vn
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 - The Manila Times
Rhythm sets May 5 earnings call, CFO due at Needham event - Stock Titan
Should I trade or invest in Rhythm Pharmaceuticals Inc2026 Fundamental Recap & Real-Time Buy Signal Alerts - baoquankhu1.vn
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Rhythm Pharmaceuticals (RYTM) Is Up 12.6% After EU IMCIVREE Expansion Boost and Board Refresh – And What's Next - Sahm
Dip Buying: Is Rhythm Pharmaceuticals Inc currently under institutional pressureGap Down & Weekly Breakout Stock Alerts - baoquankhu1.vn
Momentum Shift: What are Rhythm Pharmaceuticals Incs growth leversWeekly Trade Analysis & Weekly Setup with High ROI Potential - baoquankhu1.vn
RBC Capital Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $136 - Moomoo
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approval Expands Obesity Treatment Reach - Sahm
Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders - MSN
How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments - Yahoo Finance
Rhythm Pharmaceuticals Setmelanotide FDA Approval, Company Details, and XBRL Filing Information - Minichart
Rhythm Pharmaceuticals Announces Changes to Board of Directors - Sahm
Rhythm Pharmaceuticals adds Kim Popovits to board of directors By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals (RYTM) EVP converts RSUs, now holding 66,030 shares - Stock Titan
RHYTHM (RYTM) director receives 6,808 RSUs and 10,257 stock options - Stock Titan
Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3 - Stock Titan
Kim Popovits joins Rhythm (NASDAQ: RYTM) board as Ed Mathers exits - Stock Titan
Rhythm Pharmaceuticals, Inc. Announces Changes in Board of Directors - MarketScreener
Rhythm Pharmaceuticals adds Kim Popovits to board of directors - Investing.com
3.67%
大文字化:
|
ボリューム (24 時間):